BAY-598 (500 mg/kg, q.d.)significantly reduced tumor growth in an in vivo esophageal xenograft model only combined with doxorubicin, suggesting the potential for limitations in the application of SMYD2 inhibitors to specific anticancer drugs in response to certain types of cancer [228]. Here, SMYD2 is linked to cancer.